BRKB-201

BRKB-201 is a drug conjugate developed by BrickBio for the treatment of neoplasms and immune system diseases. It was in early discovery and preclinical development, with its highest global R&D status now listed as discontinued. The drug was being explored for indications including neoplasms (cancers) and autoimmune diseases, but there is no evidence it advanced to clinical trials or received regulatory approval. Specific details about its mechanism of action, molecular targets, or payload are not publicly disclosed. BrickBio specializes in site-specific bioconjugation technology for improved therapeutics; however, most available information on their pipeline focuses on other assets such as antibody-drug conjugates rather than specifics about BRKB-201[1][2].